CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 347 enrolled
Drug / intervention
Infliximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00036387
NCT00036387Phase 3Completed
CompareCT.gov

A Randomized, Double-blind Trial of the Safety of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis on Standard Disease-modifying Anti-Rheumatic Drug Background Therapy.

Centocor, Inc.·interventional·Posted May 10, 2002·Updated May 19, 2011

In Brief

A Phase 3 clinical trial evaluating Infliximab for Arthritis, Rheumatoid. Completed, enrolled 347 participants.

Detailed Summary

The purpose of this study is to evaluate the safety and effectiveness of Infliximab (Remicade) in patients with Rheumatoid Arthritis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce the pain of rheumatoid arthritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 10, 2002
Study CompletionNov 1, 2003
TodayJul 2, 2026
Posted 24.1 years ago

Interventions

Infliximabdrug